John Windle MD October 18 2013 Professor and Chief of Cardiology University of Nebraska Medical Center Ha ha ha Biff Guess what After we go to the drugstore and the post office ID: 775840
Download Presentation The PPT/PDF document " Atrial Fibrillation in the Era of the A..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Atrial Fibrillation in the Era of the Accountable Care Organization
John Windle MD October 18, 2013
Professor and Chief of Cardiology
University of Nebraska Medical Center
Slide2“Ha
ha
ha
, Biff. Guess what? After we go to the drugstore and the post office,
I’m
going to the vet’s to get tutored.”
Slide3Conflict of Interest
I have no relevant conflicts. Just lots of opinions
Slide4Atrial Fibrillation in the Era of the Accountable Care Organization
A Quick Review of the Basics
The importance of Definitions
The importance of atrial transport
The clinical trials that drive the guidelines
Filling in the Gaps
Rate Control versus Rhythm Control issues
Perspectives on bleeding versus stroke but not discussing new therapies.
Musings on how this might work in an ACO model
Slide5Atrial Fibrillation
Most common sustained symptomatic
tachyarrhythmia. Over 3,000,000 Americans suffer from atrial fibrillation.
Incidence
with age and presence of structural heart disease
Slightly more common in
men than women
15%(75,000 per year) of all strokes occur in AF patients
One of the top causes of
hospitalizations and extension of stays in Hospitals
Bialy et al
. Journal of the American College of Cardiology
1992; 19(3):41A.
Prystowsky
et al.
Circulation.
1996; 93(6):1262-1277.
Wolf et al.
Archives of Internal Medicine.
1987; 147(9):1561-1564.
Slide614-
12-
10-
8-
6-
4-
2-
0-
Men
Women
Men
Women
Chronic AF
Paroxysmal AF
14-
12-
10-
8-
6-
4-
2-
0-
2-yr Incidence (per 1000)
2-yr Incidence (per 1000)
12.9
6.7
5.4
2.2
0.9
0.5
4.8
1.5
0.7
0
30-39
40-49
50-59
70-79
60-69
-
-
-
-
30-39
40-49
50-59
70-79
60-69
-
-
-
-
Kannel
et al
. American Heart Journal.
1983;
106
(2):389-396.
Age
Age
12.7
4.8
0.6
0.5
0
0
0.4
0.5
1.9
9.2
Incidence of Atrial Fibrillation (Framingham Study)
Slide7Consequences of Atrial Fibrillation
Arrhythmia-associated
symptoms, look at
exertional
symptoms of shortness of breath,
exertional
dyspnea and decreased exercise tolerance.
LV
function: Impact of atrial transport and diastolic function.
Tachycardia-mediated cardiomyopathy (heart rates over 130 b/m)
2-fold in cardiac mortality
5-fold in risk of stroke
Slide8“Why do I feel like crap?”
Myocardial and Hemodynamic Consequences of Atrial fibrillation
Loss of atrial contraction decreases cardiac output
9% drop in C.O. in canine model
15% drop in C.O. in irregular response vs. same average rate pacing.
Decrease in coronary blood flow with irregular ventricular rhythm.
Tachycardia-induced cardiomyopathy (heart rate >130 for several weeks).
LVH (diastolic dysfunction) accentuates the importance atrial contraction.
Slide9The impact of atrial contribution by cardiac doppler
Slide10Atrial Fibrillation-The 3 Ps
Paroxysmal-Self-limited, often occurring in structurally normal hearts
Persistent-Requiring intervention, either chemical (antiarrhythmic drugs) or electrical to restore sinus
rhythm
Long-standing persist-a term created by cardiac electrophysiologists to “not give up”.
Permanent-”
Uncardiovertable
”
Slide11Atrial Fibrillation Guidelines
Slide12Paroxysmal Atrial Fibrillation
Vasovagal-nocturnal, triggered by stress, meals or alcohol
Self-limited but shortened duration with propafenone or flecainide
Often have pulmonary vein foci
A
menable
to Ablative therapy
Slide13Persistent Atrial Fibrillation
Need
an intervention to restore sinus rhythm
More likely to involve structural heart disease: Cardiac effects of hypertension and LVH, prior myocardial damage such as MI
Try to figure out the symptom trigger
: Rate,
regularity or Atrial
synchrony and atrial
transport.
Slide14Permanent Atrial Fibrillation
Un-cardiovertable atrial fibrillation
Duration
Left atrial size
Comorbidities
Absence of Symptoms
Slide15Conversion to NSR
Maintenance of NSR
Ventricular Rate Control
Prevention of Thromboembolism
Decision Points for Atrial
Fibrillation
NSR = normal sinus rhythm
Short Term
Long Term
Time
Slide16Rate Control Therapy
A-V Nodal Agents (slow ventricular response)
Digoxin-increases vagal tone, reduces resting heart rate but not exercise rate
Beta
Blockers-underutilized but most effective
Calcium Channel Agents
Diltiazem
and verapamil not
nifedipine
Adenosine
A-V Node Ablation with pacemaker placement
Single versus Bi-V device
Slide17Rhythm Control Therapy
Atrial Muscle Agents (restoration and maintenance of sinus rhythm)
Procainamide and Quinidine-What we learned about in School but of limited use and availability now
Propafenone
, Flecainide-Good for acute conversion and normal
hearts (Pill-in-the Pocket)
Disopyramide
-Still in good option for some, decreases vagal tone
Sotalol
and Dofetilide-
Torsades
de
Pointes but otherwise great agents
Dronederone
-very limited use.
Amiodarone*
*The Vaughn-Williams Classification system is easy but wrong.
Slide18The Affirmed Trial
The Affirmed Trial-Rate Control versus Rhythm Control in Patients with Atrial Fibrillation
Critical Study: Randomized Control Trial
Rhythm Control no better than Rate Control
Rate control less costly
Slide19The Affirmed Trial: Part II
Short follow-up on “elderly”, asymptomatic patients
Based
on an “intention to treat”
“Failure” based on first
recurrence versus time spent in desired rhythm
Very high overlap in assigned patients in their actual rhythm (sinus rhythm versus atrial fibrillation).
Not a comparison of atrial fibrillation versus sinus rhythm
(The sinus rhythm patients did significantly better)
Slide20Atrial Fibrillation; now what?!
No significant improvement in quality of life with “rhythm control” strategy in multiple trials above. STAF and HOT CAFÉ showed increase in exercise tolerance.
Slide21It’s just AF; it won’t KILL ME.
HF promotes AF, AF exacerbates HF, and patients with either who develop the other, share a poor prognosis.
Stroke in AF averages 5% per year!1.5% annual in 50-59y to 23% annual in 80-89 yrs.
Framingham Heart Study (1983);The Regional Heart Study Whitehall StudyManitoba Study (1995)
Framingham Data.
Excess mortality in AF patients compared to matched (non-AF).
Slide22My Take Home Messages:
Yep-Sinus rhythm and rate controlled atrial fibrillation equivalent in asymptomatic, elderly patients followed over 3-5 years.
Yep-Lower utilization of resources with rate control strategy
But,
Didn’t answer sinus versus rate control
Most of my patients are not truly asymptomatic
Atrial fibrillation causes a 5-10% drop in EF in most patients, what do you think will happen over time?
Slide23Anticoagulation
Anticoagulation is recommended for ALL patients with atrial fibrillation, except those with “LONE AF” or contraindications.Anticoagulation with a vitamin K antagonist is recommended for patients with more than 1 moderate risk factorAspirin 81-325 mg for low-risk patients, or those with CI to oral anticoagulationAnticoagulation for atrial flutter is recommended as per AF.Long term anticoagulation with vitamin K antagonist is NOT recommended for primary strike prevention in patients <60 yrs of age without heart disease.
CHADS
2
Score
EF <35%
Slide24Circulation. 2006;114:e257-e357.
Slide25Why anticoagulation to a target of 2.0 to 3.0?
Why not everyone with AF?
Warfarin
vs. Aspirin
Slide26Atrial Fibrillation: Interventions
Cardioversion: Medical versus Electrical
Dual Chamber
Pacing (
Bradycardic
-dependent arrhythmias)
AV Node Ablation and Ventricular
Pacing
EF <45%
Pacing over 40%
Pulmonary Vein Isolation Ablation
Surgical MAZE Procedure
Slide27Dilbert
Dilbert
Slide28All roads lead to catheter ablation!
Slide29Catheter Ablation for AF
Rationale:
Triggers within the pulmonary veins and other sites (SVC, LM, CS, CT)
Isolation of the pulmonary veins eliminates AF in many patients with PAF.
Alteration of substrate in Persistent AF patients dramatically reduces symptoms of AF, and frequently reduces or eliminates the need for antiarrhythmic medications to control the rhythm.
Slide30History of AF Ablation
Initial procedure mimicked the surgical maze procedure. Success rate was 40-50% and complication rate high. (Prior to 1998).Automaticity within the pulmonary veins was then the target…
Slide31Pulmonary Vein Isolation
~95% of the triggers for AF are suspected to be in the pulmonary veins.
Additional triggers at sites of “Complex Fractionated Atrial Electrograms” (CFAEs)
In PAROXYSMAL atrial fibrillation, pulmonary vein isolation is effective in 80-85% of cases at “CURING” atrial fibrillation.
Currently, “Symptomatic atrial fibrillation refractory to or intolerant of medical therapy” is the primary indication for PVAI.
Slide32Ultrasound
Reconstruction of
The Left Atrium with CartoSound/ICE
WHAT FOR:
Mapping veins, appendage
Mitral annulus/valve
Velocities, evaluate for PFO
Map coronary arteries
CONTINUOUSLY EVALUATE
FOR PERICARDIAL
EFFUSION
Slide33CT scan merged with ultrasound image (right).
Slide34Slide35Pulmonary vein isolation for paroxysmal AF
Slide36Atrial fibrillation persists within the RSPV, but sinus rhythm is present elsewhere
Slide37What about “Non-Paroxysmal” AF?
More complex disease entity from an ablation standpoint.
PVAI is not sufficient for elimination of atrial fibrillation in many patients.
Additional lesions include approximation of the maze lesion set with ablation at the roof, mitral annulus, cavotricuspid isthmus, and svc.
The addition of CFAE ablation is of unclear benefit and remains controversial.
Slide38Complications:
Perforation with pericardial tamponade
~1% of cases of PVAI (up to 5% depending on series)
Usually self-limiting, requiring a drain
Rarely can require surgical drainage/repair.
Cerebrovascular accidents
0.5 to 2.5% of cases
Dramatically reduced with higher ACT
Phrenic Nerve Injury
0.1 to 0.48% of cases
Recovery in 66% of cases, can be permanent
Radiation related
Fluoroscopy times can be prolonged.
Pulmonary vein stenosis
1 to 2% with current techniques
(15-20% historically)
Atrio
-Esophageal fistula
Slide39New Ablation Tools and Techniques
CryoBalloon (Arctic Front)Ablation Frontiers CatheterHigh-Intensity Focused UltrasoundLaser ablation And more…. Just around the corner.
Slide40Where Do We Go From Here?
3,000,000 patients how do we divide up the work?
Base-rate theory: EP>Cardiology>Primary Care
Team-based Care
Decision-making
Rate versus rhythm control
Antithrombotic Care
Slide41Where do we go from here: the ACO
In my “perfect-world”
EP physicians would consult (either actual or virtually) on all patients at presentation of their atrial fibrillation
The EP physician, the primary care provider and the patient would develop a consensus treatment plan with all three holding accountability for the outcome.
If anti-thrombotic therapy was initiated it would be managed by a non-physician team member under protocol.
Cardiologists would be involved in atrial
fibrillation management.
Slide42Questions?
Slide43New Drugs
Dronedarone
: a non-iodinated amiodarone analog.
Trials have compared the medication to placebo and amiodarone.
Euridis
and Adonis (European and American) trials showed efficacy relative to placebo.
ANDROMEDA study showed higher death rate in NYHA Class IV patients.
ATHENA trial demonstrated stroke risk reduction.
Currently, approval is for “treatment of patients with a history of, or recurrent atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition.”
Slide44Azmilide
Not yet approved
Potassium blocker similar to dofetilide or sotalol, but blocks both
iKr
and
iKs
.
Does not perform as a beta-blocker.
LONG HALF-LIFE of up to 4 days.
In a trial to assess its efficacy in MI patients with EF 15-35%, (ALIVE), a higher proportion of patients in the treatment arm were in sinus rhythm at the end of the study…
Placebo-controlled trial is in the works.